Sarepta Therapeutics Inc
SRPT
查看详细走势图
21.290USD
+0.250+1.19%
交易中 （美东）报价延迟15分钟
2.23B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.19%
5天
-1.11%
1月
+20.35%
6月
+6.03%
今年开始到现在
-82.49%
1年
-82.10%
查看详细走势图
TradingKey Sarepta Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Sarepta Therapeutics Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名90/158位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价29.46。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sarepta Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
28
位分析师
持有
评级
29.457
目标均价
+34.75%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sarepta Therapeutics Inc亮点
亮点风险
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
业绩高增长
公司营业收入稳步增长，连续3年增长103.85%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值-7.79，处于3年历史合理位
机构减仓
最新机构持股84.30M股，环比减少20.58%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值11.84K
活跃度降低
近期活跃度降低，过去20天平均换手率2.36
Sarepta Therapeutics Inc新闻
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sarepta Therapeutics Inc简介
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
公司代码SRPT
公司Sarepta Therapeutics Inc
CEOIngram (Douglas S)
网址https://www.sarepta.com/
常见问题
Sarepta Therapeutics Inc(SRPT)的当前股价是多少？
Sarepta Therapeutics Inc(SRPT)的当前股价是 21.290。
Sarepta Therapeutics Inc的股票代码是什么？
Sarepta Therapeutics Inc的股票代码是SRPT。
Sarepta Therapeutics Inc股票的52周最高点是多少？
Sarepta Therapeutics Inc股票的52周最高点是129.840。
Sarepta Therapeutics Inc股票的52周最低点是多少？
Sarepta Therapeutics Inc股票的52周最低点是10.415。
Sarepta Therapeutics Inc的市值是多少？
Sarepta Therapeutics Inc的市值是2.23B。
Sarepta Therapeutics Inc的净利润是多少？
Sarepta Therapeutics Inc的净利润为235.24M。
现在Sarepta Therapeutics Inc(SRPT)的股票是买入、持有还是卖出？
根据分析师评级，Sarepta Therapeutics Inc(SRPT)的总体评级为持有，目标价格为29.457。
Sarepta Therapeutics Inc(SRPT)股票的每股收益（EPS TTM）是多少
Sarepta Therapeutics Inc(SRPT)股票的每股收益（EPS TTM）是-2.700。
相关品种
